1525.1 – Low dose rate brachytherapy for intermediate and high-risk prostate cancer

Page last updated: 18 July 2023

Application Detail

Description of Medical Service

LDR Brachytherapy is the insertion of tiny radioactive capsules or ‘seeds’ into the prostate gland. Generally, 80-120 seeds will be implanted. The radiation from the seeds targets the tumour and destroys the cancerous cells. The seeds are inserted via a hollow needle through the perineum. The procedure is guided by transrectal ultrasound.

Description of Medical Condition

Cancer of the prostate gland that is classified as intermediate or high-risk. Intermediate risk prostate cancer is defined as having a Prostate Specific Antigen (PSA) measurement of 10-20 nanograms per millilitre of blood (ng/ml) and/or a Gleason score of 7 and/or a tumour classified as T2b-c. High-risk prostate cancer is classified as having a PSA of greater than 20 and/or a Gleason score of 8-10 and/or a tumour classified as T3 OR 2 or more intermediate risk features.

Reason for Application

Amendment to MBS item(s)

Medical Service Type


Previous Application Number


Associated Documentation

Application Form

Application Form (PDF 1230 KB)
Application Form (Word 162 KB)

Consultation Survey

Consultation Survey (PDF 323 KB)
Consultation Survey (Word 72 KB)

MSAC Consultation
MSAC consultation input closed Friday, 10 February 2023.

For further information please refer to PASC, ESC, MSAC Key Dates
For further information on the consultation process please refer to MSAC Consultation Process

PICO Confirmation


Assessment Report


Public Summary Document

Public Summary Document (PDF 625 KB)
Public Summary Document (Word 176 KB)

Meetings for this Application


Bypassing PASC


9-10 February 2023


30-31 March 2023